Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-Cigarettes

Tobacco Use Clinical Trial

Official title:

Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-Cigarettes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03277495
• Other study ID #: 2017-0948
• Secondary ID: 1U01DA045524-01
• Status: Recruiting
• Phase: N/A
• Start date: July 12, 2023
• Est. completion date: August 31, 2024

Study information

• Verified date: August 2023
• Source: University of Illinois at Chicago
• Contact: Kathleen Diviak, PhD
• Phone: 312-996-2327
• Email: kdiviak[@]uic.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary goal of this study is to examine whether cigarette smokers can reduce their use of conventional, combustible cigarettes by switching to a Standardized Research E-Cigarette (SREC); whether participants can maintain these reductions and use of SRECs over a 12-week period; and whether there are changes in subjective and objective measures of health, appeal and acceptability of the products used during this time frame.

Description:

The investigators will enroll 120 conventional cigarette smokers who report smoking at least 3 cigarettes/day. Following completion of baseline questionnaires and a week of ecological momentary assessments (EMA) tracking participants usual smoking behavior, participants will be stratified (by sex) and randomly assigned with a 1:1 allocation ratio to one of two conditions: 1) to receive SREC pods in their usual flavor (N = 60); and 2) to receive SREC pods in their choice of flavor (N = 60). The SREC pods used in this study come in tobacco, menthol, blueberry, and watermelon flavors. No other flavors will be available to use with the SREC.

Counseling at Week 2. Participants in both conditions will receive brief behavioral counseling on reducing their combustible cigarette use by substitution with SREC. Staff will work with participants to set individual goals for reduction during this first week, with the goal of achieving at least 75% reduction in the number of combustible cigarettes smoked by the end of the week, and all are encouraged to reduce further. Participants will also be told not to use any other combustible tobacco products. During the week, participants will complete a daily text or web report on number of cigarettes smoked and SREC pods used.

Week 3 Visit. Participants will bring back all used and unused pods for adherence counts, complete a brief questionnaire about subjective reactions and potential adverse effects, and provide breath CO. Participants will meet with study staff to review their progress with switching to SREC and receive continued behavioral counseling to substitute SREC for cigarettes. Participants will receive SREC refill pods and will start a second 7-day EMA protocol.

Week 4 Visit. EMA debriefing to check for compliance and any problem reports; return of used and unused pods, complete assessments; review of progress with switching to SREC. Participants will receive a 2 week supply of SREC pods.

Weeks 5-13. Participants return to the study office every 2 weeks to return pods, receive a new supply, and provide breath CO. During the week, participants will continue daily use reports via web/text.

Week 14 (End-of-Treatment). Participants return to the study office to complete a full assessment battery. They will be encouraged to continue to stay off/reduce all combustible cigarettes, but will not receive additional SREC refills from the study.

Week 18 (One Month Follow-up). Participants complete a final survey.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: August 31, 2024
• Est. primary completion date: April 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. men and women 21 years of age or older;

2. daily smoking rate of 3 cigarettes/day or greater for at least one year;

3. interested in reducing cigarette use;

4. willing to try e-cigarettes;

5. able to attend in-person assessments over the next 5 months;

6. English speaking; and

7. breath CO of 3ppm or greater (assessed at baseline visit). Women who are of child-bearing age cannot be pregnant and must agree to use an approved form of birth control during the study.

Exclusion Criteria:

1. current use of any smoking cessation medication or participation in a smoking cessation program or study;

2. current daily ENDS user;

3. pregnancy if female; and

4. no two members of the same household may participate in this study.

Related Conditions & MeSH terms

• Tobacco Use

Intervention

Behavioral:
• Brief behavioral counseling
Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention

Locations

Country	Name	City	State
United States	Institute for Health Research and Policy	Chicago	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
University of Illinois at Chicago	National Institute on Drug Abuse (NIDA), University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	CO level	in ppm	12-weeks
Other	Blood Pressure	systolic blood pressure and diastolic blood pressure in mm hg	12-weeks
Other	Heart Rate	beats per minute	12-weeks
Other	Weight	in pounds	12-weeks
Other	self-report of respiratory symptoms	The St. George's Respiratory Questionnaire (SGRQ)	12-weeks
Other	nicotine dependence	Fagerstrom Test for Nicotine Dependence	12-weeks
Primary	Combustible cigarette use	number of cigarettes smoked per week	12-weeks (end of treatment)
Secondary	Abstinence	The proportion of participants who achieve total abstinence from combustible cigarettes (defined as no cigarette smoking in the past 7 days)	12-weeks (end of treatment)
Secondary	Number of cigarettes smoked	The total number of cigarettes smoked in the 7 days prior to the last assessment	18-weeks (end of trial)